Introduction
Higher plants produce diverse low-molecular-weight chemicals such as alkaloids, terpenoids and phenylpropanoid compounds (Croteau et al., 2000) .
Although these compounds are widely used for health and nutrition in humans, alkaloids are particularly important in medicine due to their high biological activities.
However, the low yield of metabolites, especially alkaloids, in plants limits large-scale development of the plant natural product industry. Thus, many research groups have tried to establish production systems using the micropropagation of elite plant clones, cell culture and organ culture based on incomplete information regarding biosynthesis of these metabolites. Over the past 20 years, our understanding of the biochemistry and molecular biology of natural products, including alkaloids, has rapidly expanded.
Based on knowledge regarding biosynthetic enzymes and their corresponding genes, the modification of productivity and metabolic profiles has become possible (Sato et 
Isoquinoline alkaloid biosynthesis and pathway characterization
Due to technological difficulties in the cultivation and relatively slow growth of medicinal plants, plant cell and tissue cultures have been intensively examined for the production of secondary metabolites (Sato & Yamada, 2008; Verpoorte et al., 1991) .
Whereas the selection of high-yield lines and treatment with an elicitor such as methyl jasmonate has enabled the industrial production of some metabolites, e.g., shikonin-production in selected Lithospermum erythrorhizon cells, or paclitaxel production in Pacific yew cell cultures with methyl jasmonate, it is quite difficult to achieve both high productivity and stability for industrial application (Sato & Yamada, 2008) . While the development of hairy roots by the transformation of plant cells with Agrobacterium rhizogenes provides a solution with unlimited growth, morphological differentiation of roots for physical strength, high potential for the mass-production of valuable secondary metabolites, and greater genetic stability, for fermentation, we need a much faster growth of cells/tissues, higher productivity and improved quality of metabolites (for details of cell culture techniques, please see Sato & Yamada, 2008) .
Recent advances in molecular biology have provided tools for metabolic engineering. The identification of many genes of biosynthetic enzymes and characterization of the spatial and developmental regulation of their expression have clarified their roles in the biosynthesis of secondary metabolites and provided strategies for metabolic engineering such as the trimming of undesired pathways, the enhancement of rate-limiting steps and the introduction of new pathways to produce novel compounds (Sato et al., 2007a,b) .
Isoquinoline alkaloid (IQA) biosynthesis provides a good model in metabolic engineering, since it has been intensively studied at the molecular level and experimentally challenged. The biosynthetic pathway for IQAs starts with L-tyrosine, as shown in Figure 1 . Among IQAs, the biosynthesis of benzylisoquinoline alkaloid from norcoclaurine has been the most investigated to date. All of the enzyme genes of the total nine enzymatic reaction steps from norcoclaurine to berberine have been characterized at the DNA level ( To increase metabolite diversity, we ectopically expressed CjSMT, which is involved in berberine biosynthesis but not in benzophenanthridine alkaloid biosynthesis, in California poppy (E. californica) cells ( (Fig. 6) .
However, there is another pitfall in effective gene silencing; e.g., an enhanced branch pathway from the accumulated reticuline to produce a byproduct, i.e., 
Perspectives
While the biosynthetic pathways for many metabolites still require considerable characterization including of the involved enzymes and their genes, and cons. For instance, while plant cell or tissue cultures can produce more divergent chemicals than microbial systems, their complexity and instability are problematic for industrial production. Microbial systems enable alkaloid production on a relatively large scale within a short period, but require more molecular informations on the biosynthetic pathways and enzymes, whereas the emergence of synthetic biology offers the possibility of improving the production of useful products through the design and engineering of complex biological systems. While computer-assisted molecular design software is being developed to facilitate the synthesis of novel compounds with drug-like properties and desired activities, the use of information science for the reconstruction of metabolic pathways, i.e., "retrobiosynthetic" systems, will require more experimental data on the identification and analysis of biosynthetic enzymes and pathways. However, technological progress has been quite rapid and provides us with many options. The potentials of metabolic engineering in secondary metabolism are unlimited.
Conclusion
Metabolic engineering as well as synthetic biological approaches are at the forefront in natural product research. Our experiences in IQA biosynthesis provide new clues for the molecular characterization of biosynthetic pathways and novel production systems for natural products. Technological advances, including next-generation sequencing, offer a bright future for the production of not only IQAs but also other alkaloids. This high potential in natural product research will require more sophisticated techniques as we move from metabolites to drug discovery. 
Metabolic diversification by the introduction of a branch pathway
The introduction of a novel branch pathway in California poppy induced the production of uncommon protoberberine-type alkaloids, whereas major products were further metabolized to di-methoxy-type benzophenanthridine alkaloids by endogenous enzymes. 
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